ESTRELLA IMMUNOPHARMA, INC. Noncash or Part Noncash Acquisition, Payables Assumed
ESTRELLA IMMUNOPHARMA, INC. (ESLA) reported Noncash or Part Noncash Acquisition, Payables Assumed of $730.00 thousand for the 12-month period ending 2024-06-30, per its 10-KT filed 2025-03-25.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NoncashOrPartNoncashAcquisitionPayablesAssumed1 · last filed 2025-03-25
- ESTRELLA IMMUNOPHARMA, INC. noncash or part noncash acquisition, payables assumed for the quarter ending 2024-06-30 was $0.00.
- ESTRELLA IMMUNOPHARMA, INC. noncash or part noncash acquisition, payables assumed for the quarter ending 2024-03-31 was $0.00.
- ESTRELLA IMMUNOPHARMA, INC. noncash or part noncash acquisition, payables assumed for the quarter ending 2023-12-31 was $0.00.
- ESTRELLA IMMUNOPHARMA, INC. noncash or part noncash acquisition, payables assumed for the quarter ending 2023-09-30 was $730.00K.
- ESTRELLA IMMUNOPHARMA, INC. noncash or part noncash acquisition, payables assumed for fiscal 2024 was $730.00K.
| Period end | Noncash or Part Noncash Acquisition, Payables Assumed 3 month | Noncash or Part Noncash Acquisition, Payables Assumed 6 month | Noncash or Part Noncash Acquisition, Payables Assumed 9 month | Noncash or Part Noncash Acquisition, Payables Assumed 12 month |
|---|---|---|---|---|
| 2024-06-30 | $0.00 derived: 10-KT 12 month − 10-Q 9 month · filed 2025-03-25 | $0.00 derived: sum of 2 quarters · filed 2025-03-25 | $0.00 derived: sum of 3 quarters · filed 2025-03-25 | $730.00K 10-KT · filed 2025-03-25 |
| 2024-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-15 | $0.00 derived: sum of 2 quarters · filed 2024-05-15 | $730.00K 10-Q · filed 2024-05-15 | |
| 2023-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-14 | $730.00K 10-Q · filed 2024-02-14 | ||
| 2023-09-30 | $730.00K 10-Q · filed 2024-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |